uniQure (NASDAQ:QURE) Trading 5.4% Higher – What’s Next?

Shares of uniQure N.V. (NASDAQ:QURE) rose 5.4% on Wednesday . The company traded as high as $25.30 and last traded at $25.4740. Approximately 211,890 shares changed hands during trading, a decline of 91% from the average daily volume of 2,302,502 shares. The stock had previously closed at $24.18.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Royal Bank Of Canada lowered their target price on uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research note on Monday, November 3rd. Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a research note on Monday, December 8th. Stifel Nicolaus decreased their target price on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Wells Fargo & Company dropped their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 12th. Finally, Guggenheim increased their price objective on uniQure from $28.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $60.82.

uniQure Price Performance

The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The stock has a market capitalization of $1.57 billion, a P/E ratio of -5.74 and a beta of 0.59. The stock’s fifty day moving average is $35.87 and its 200-day moving average is $26.81.

uniQure (NASDAQ:QURE) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. On average, equities analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current year.

Insiders Place Their Bets

In other uniQure news, CFO Christian Klemt sold 15,000 shares of the business’s stock in a transaction on Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the completion of the transaction, the chief financial officer owned 217,730 shares of the company’s stock, valued at $11,975,150. The trade was a 6.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jack Kaye sold 38,810 shares of the company’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the sale, the director owned 20,439 shares of the company’s stock, valued at $620,119.26. This trade represents a 65.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 85,244 shares of company stock valued at $2,859,386 over the last 90 days. 4.79% of the stock is currently owned by company insiders.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Jefferies Financial Group Inc. bought a new stake in shares of uniQure in the second quarter valued at approximately $29,217,000. Vestal Point Capital LP increased its position in uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock worth $50,801,000 after acquiring an additional 1,767,572 shares during the period. JPMorgan Chase & Co. raised its stake in uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after purchasing an additional 1,491,486 shares during the last quarter. Fred Alger Management LLC bought a new stake in uniQure in the 3rd quarter valued at $75,320,000. Finally, Sofinnova Investments Inc. grew its position in uniQure by 185.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after purchasing an additional 1,012,585 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.